Number of Students Accepted Sample Clauses

Number of Students Accepted. Each academic year, a maximum of five (5) students will be accepted by LECOM into Phase II from University of Pittsburgh - Bradford's Early Acceptance Program.
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Number of Students Accepted. 1) No more than twenty (20) students from NTU shall be accepted for any given academic year at the UAlbany, unless otherwise agreed to mutually in writing by NTU and UAlbany.
Sample 1
Number of Students Accepted. Each academic year, only five (5) students will be accepted by LECOM into LECOM's Pharmacy Program(s) from The University of Pittsburgh at Bradford's Accelerated Pharmacy Program.
Sample 1
Number of Students Accepted. Each academic year, a maximum combined total (Bradenton campus and Erie campus) of five (5) students will be accepted by LECOM into Phase II from JCC's EAP. To allow for attrition from the time of EAP enrollment until LECOM matriculation, up to 10 JCC students with the same year of LECOM matriculation may be enrolled in Phase I of the EAP. Should more than 5 of the 10 enrolled students meet the final acceptance criteria, LECOM will permit them to matriculate. JCC and LECOM reserve the right to limit the number of students enrolled in this EAP. LECOM reserves the right to amend this agreement to either increase or decrease the number of students accepted for LECOM matriculation each academic year. LECOM will notify JCC of its intent to change the number of students accepted for LECOM matriculation each academic year from JCC at least 12 months prior to making the change The decision to increase the number of EAP students accepted for LECOM matriculation will be based upon seat availability at LECOM and a demonstration by JCC that more than 10 students could advance to Phase II of the EAP. A decrease in the number of EAP students accepted for LECOM matriculation will be based upon seat availability at LECOM.
Sample 1
Number of Students Accepted. Pages 4 2.5. Application to EAP Pages 4-5 2.6. Interviews Page 5 2.7. Provisional Acceptance Page 6 2.8. Student Inquiries Page 6 2.9. Student Responsibility Page 7 2.10. JCC / LECOM Responsibility Page 8 2.11. Representatives Pages 8-9 2.12. Annual Reviews Page 9 3. Article III: Program Timeline Page 9
Sample 1
Number of Students Accepted. Each academic year, a combined total (Bradenton campus, Erie campus, and DLP) of five (5) qualified students will be accepted into Phase I of the EAP. LECOM and JCC may mutually agree, for any given year, to admit more than five students.
Sample 1

Related to Number of Students Accepted

  • Number of Students 6.2.2.1.1 Except as herein provided, Instructors shall have at any time no more than an average of thirty-five (35) students per instructional section, averaged over all instructional sections assigned to the instructor.

  • Study Population The study was based at the San Francisco KPNC Anal Cancer Screening Clinic. We enrolled men who were identified as positive for HIV through the Kaiser HIV registry, who were aged ≥ 18 years, who were not diag- nosed with anal cancer before enrollment, and who pro- vided informed consent. In total, 363 men were enrolled between August 2009 and June 2010. The study was reviewed and approved by the institutional review boards at KPNC and at the National Cancer Institute. All partici- pants were asked to complete a self-administered ques- tionnaire to collect risk factor information. Additional information regarding HIV status and medication, sexu- ally transmitted diseases, and histopathology results were abstracted from the KPNC clinical database. For 87 of the 271 subjects without biopsy-proven AIN2 or AIN3 at the time of enrollment, follow-up infor- mation concerning outcomes from additional clinic visits up to December 2011 was available and included in the analysis to correct for the possible imperfect sensitivity of high-resolution anoscopy (HRA).13,15 Clinical Examination, Evaluation, and Results During the clinical examination, 2 specimens were col- lected by inserting a wet flocked nylon swab16 into the anal canal up to the distal rectal vault and withdrawing with rotation and lateral pressure. Both specimens were trans- ferred to PreservCyt medium (Hologic, Bedford, Mass). A third specimen was collected for routine testing for Chla- mydia trachomatis and Neisseria gonorrhea. After specimen collection, participants underwent a digital anorectal ex- amination followed by HRA. All lesions that appeared sus- picious on HRA were biopsied and sent for routine histopathological review by KPNC pathologists, and were subsequently graded as condyloma or AIN1 through AIN3. No cancers were observed in this study population. From the first specimen, a ThinPrep slide (Hologic) was prepared for routine Xxxxxxxxxxxx staining and xxxxx- xxxxx. Two pathologists (T.D. and D.T.) reviewed the slides independently. Cytology results were reported anal- ogous to the Bethesda classification17 for cervical cytology except when otherwise noted. The following categories were used: negative for intraepithelial lesion or malig- xxxxx (NILM); ASC-US; atypical squamous cells cannot rule out high-grade squamous intraepithelial lesion (HSIL) (ASC-H); low-grade squamous intraepithelial lesion (LSIL); HSIL, favor AIN2 (HSIL-AIN2); and HSIL-AIN3. ASC-H, HSIL-AIN2, and HSIL-AIN3 were combined into a single high-grade cytology category for the current analysis. Biomarker Testing Using the residual specimen from the first collection, mtm Laboratories AG (Heidelberg, Germany) performed the p16INK4a/Ki-67 dual immunostaining (‘‘p16/Ki-67 staining’’) using their CINtec Plus cytology kit according to their specifications. A ThinPrep 2000 processor (Holo- gic) was used to prepare a slide, which then was stained according to the manufacturer’s instructions. The CINtec Plus cytology kit was then applied to the unstained cytol- ogy slide for p16/Ki-67 staining. On the second collected specimen, Roche Molecular Systems (Pleasanton, Calif) tested for HR-HPV, includ- ing separate detection of HPV-16, and HPV-18 DNA, using their cobas 4800 HPV test. To prepare DNA for the cobas test, automated sample extraction was per- formed as follows: 500 lL of the PreservCyt specimen was pipetted into a secondary tube (Falcon 5-mL polypropyl- ene round-bottom tube, which measured 12-mm-by-75- mm and was nonpyrogenic and sterile). The tube was capped, mixed by vortexing, uncapped, placed on the x-480 specimen rack, and loaded onto the x-480 sample extraction module of the cobas 4800 system. The x-480 extraction module then inputs 400 lL of this material into the specimen preparation process. The extracted DNA was then tested as previously described.16 NorChip AS (Klokkarstua, Norway) also tested the second specimen for HPV-16, -18, -31, -33, and -45 HPV E6/E7 mRNA using their PreTect HPV-Proofer assay according to their specifications. All testing was per- formed masked to the results of the other assays, clinical outcomes, and patient characteristics.

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Eligible Population 5.1 Program eligibility is determined by applicable law set forth in Program rules and the requirements established in the Program Policy Manual.

Time is Money Join Law Insider Premium to draft better contracts faster.